Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Has Consensus Target Price of $34.43 According to Analysts

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $34.43.

Several equities research analysts have recently commented on NRIX shares. Stifel Nicolaus set a $41.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, October 13th. Wells Fargo & Company cut their price target on shares of Nurix Therapeutics from $25.00 to $20.00 and set an “overweight” rating for the company in a report on Wednesday, November 4th. Needham & Company LLC reissued a “buy” rating and set a $34.00 price target on shares of Nurix Therapeutics in a report on Tuesday, October 13th. Truist Financial reduced their price target on shares of Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, October 13th. Finally, Robert W. Baird upped their price objective on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 13th.

Read Our Latest Stock Analysis on NRIX

Insider Activity

In other news, Director Julia Gregory sold 22,583 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $23.40, for a total value of $528,442.20. Following the completion of the transaction, the director owned 10,750 shares in the company, valued at approximately $251,550. The trade was a 67.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gwenn Hansen sold 3,957 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $26.28, for a total value of $103,989.96. Following the completion of the transaction, the insider directly owned 123,452 shares in the company, valued at $3,244,318.56. The trade was a 3.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 38,499 shares of company stock worth $893,645. Insiders own 6.70% of the company’s stock.

Institutional Trading of Nurix Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in Nurix Therapeutics during the 2nd quarter worth about $212,769,000. Trails Edge Capital Partners LP bought a new position in shares of Nurix Therapeutics in the 2nd quarter valued at about $38,166,318. Marshall Wace LLP bought a new position in shares of Nurix Therapeutics in the 3rd quarter valued at about $20,693,000. Bank of America Corp DE bought a new position in shares of Nurix Therapeutics in the 2nd quarter valued at about $20,429,000. Finally, Goldman Sachs Group Inc. grew its position in shares of Nurix Therapeutics by 57.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,281,782 shares of the company’s stock worth $30,391,000 after buying an additional 468,193 shares during the period.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock opened at $13.60 on Tuesday. The company has a market capitalization of $1.49 billion, a PE ratio of 5.89 and a beta of 1.80. Nurix Therapeutics has a one year low of $13.55 and a one year high of $28.23. The business has a 50 day simple moving average of $22.31 and a 200 day simple moving average of $20.07.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $4.73 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. The firm had revenue of $673.06 million for the quarter, compared to analysts’ expectations of $24.35 million. Equities analysts anticipate that Nurix Therapeutics will post 1.14 earnings per share for the current fiscal year.

About Nurix Therapeutics

(Get Free Report)

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company’s technology focuses on protein degradation, using the cell’s natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down.

Further Reading

Analyst Recommendations for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.